Download PDF
Open Access
CC BY 4.0 · Endoscopy 2022; 54(12): 1139-1146
DOI: 10.1055/a-1838-5642
Original article

Self-expandable duodenal metal stent placement for the palliation of gastric outlet obstruction over the past 20 years

Authors

  • Agnes N. Reijm   *

    1   Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands

  • Pauline A. Zellenrath   *

    1   Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands

  • Ruben D. van der Bogt

    1   Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands

  • Lydi M. J. W. van Driel

    1   Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands

  • Peter D. Siersema

    2   Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands

  • Marco J. Bruno

    1   Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands

  • Manon C. W. Spaander 

    1   Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
Further Information
Also available at
  Permissions and Reprints

Referred to by:

Author commentary on Agnes N. Reijm et al.Endoscopy 2022; 54(12): v42-v42
DOI: 10.1055/a-1895-7526

Abstract

Introduction Duodenal stent placement is a palliative option for management of malignant gastric outlet obstruction (GOO). In the last 20 years, management of gastrointestinal cancers has considerably changed. It is unknown if these changes have affected clinical outcome of duodenal stent placement.

Methods Retrospective cohort study conducted in a tertiary referral center. Patients who underwent duodenal stent placement for GOO-symptoms due to a malignant stricture were included. Primary outcome was GOO-symptom free survival. Secondary outcomes included stent-related adverse event rates. Potential explanatory parameters such as period of stent placement (1998–2009 vs 2010–2019), prior treatments, peritoneal deposits, and stricture length were evaluated using multivariable Cox regression analysis.

Results A total of 147 patients (62 % male; median age 64 years) were included. After a median of 28 days after stent placement, 82 patients (57 %) had recurrent GOO-symptoms. GOO-symptom free survival was significantly lower in 2010–2019 (P < 0.01). Time period was the only independent predictor for reduced GOO-symptom free survival (HR 1.76, P < 0.01). Stent-related adverse event rates increased over time (1998–2009: 31 % vs 2010–2019: 37 %). Prior treatment with chemotherapy and/or radiotherapy was significantly associated with an increased risk of adverse events (OR 2.53, P = 0.02).

Conclusions Clinical outcome of duodenal stent placement did not improve over time. The decreased GOO-symptom free survival and increased adverse event rate in more recent years are probably related to the chemo- and/or radiotherapy treatment provided prior to duodenal stent placement.

* Both authors contributed equally.


Supplementary material



Publication History

Received: 23 December 2021

Accepted after revision: 27 April 2022

Accepted Manuscript online:
28 April 2022

Article published online:
23 June 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany